Triple-negative breast cancer (TNBC), defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, has limited targeted therapy options and is associated with a poor prognosis after conventional chemotherapy (4). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.